Corticosteroid lipophilicity is a more important determinant of corticosteroid uptake into human hepatocytes than serum protein binding Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Pronounced tissue and plasma protein binding of ciclesonide is responsible for reduced pharmacodynamic potency in the lung Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Different tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Eur Respir J 2006; 28: Suppl. 50, 433s Year: 2006
Tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Effect of intermittent hypoxia on the expression of fatty acid binding proteins in human adipocytes and macrophages Source: Annual Congress 2011 - Obstructive sleep apnoea: inflammation and metabolism Year: 2011
Uptake, retention and metabolism of ciclesonide in human alveolar epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
TGFβ-induced proteoglycan production and α-smooth muscle actin expression in cultured human lung fibroblasts is inhibited by combination of budesonide and formoterol Source: Eur Respir J 2004; 24: Suppl. 48, 251s Year: 2004
Pulmonary targeting of ciclesonide and its active metabolite as determined in an ex-vivo rat receptor-binding assay Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002
The effect of metabolite 1 of erdosteine on the elatase release from human neutrophils Source: Eur Respir J 2005; 26: Suppl. 49, 100s Year: 2005
In vitro anti-inflammatory activity of the new glucocorticoid ciclesonide in human cellsSource: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
Partial characterisation of a PLA2 -like activity in human lipoprotein-free serum, which inactivates secreted phosphatidylcholine from cultured foetal rat type II cells Source: Eur Respir J 2004; 24: Suppl. 48, 108s Year: 2004
Proteoglycan production in cultured human lung fibroblasts is synergistcally inhibited by combination of budesonide and formoterol Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003
An in vitro method showing the atrophic effect of the COPD serum on healthy human myotubes Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases Year: 2019
Low concentration of phenol in medical solutions can induce bronchoconstriction and toxicity in murine, rat and human lungs. Source: International Congress 2018 – Basic pharmacology Year: 2018
Glycosaminoglycan synthesis is modulated by ciclesonide in human lung cells Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004
Effects of TGF-beta and budesonide on MAPK phosphorylation, IL-6/IL-11 secretion, and cell proliferation in human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 662s Year: 2006
Low expression of cellular retinoic acid binding protein 2 and dysregulation of elastin expression in pulmonary emphysema fibroblasts Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008
Synergistic action of formoterol on budesonide-generated decrease of proteoglycan production by activated lung fibroblasts is mediated via β-adrenergic receptor and is dependent on glucocorticoid receptor Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Highly lipophilic fatty acid esters of the active metabolite of ciclesonide formed in vitro in rat lung tissue Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004